Market Overview

Shares of Omeros Bounce Over $5.40 Following Mid-Day Comments from MLV's Zavoico


MLV analyst George Zavoico issued an intraday research note on Omeros Corp. (NASDAQ: OMER) Monday afternoon. While the stock is still down about 3 percent for the session, the price bounced off an afternoon low around $5.38.

The analyst highlighted the combination of clinical trial programs underway for OMS721 and OMS824 by year end and the commercial launch of OMS302 as making Omeros shares a "compelling investment opportunity that we think is undervalued at this time."

Zavoico is expecting "Omeros to add to its cash reserves by the sale of newly issued stock or, preferably, by establishing a collaborative partnership agreement for at least one of its drug candidates" by the end of 2013.

The MLV analyst maintains a Buy rating and $14 price target on shares of Omeros.

Latest Ratings for OMER

May 2019Initiates Coverage OnOverweight
Aug 2018MaintainsBuyBuy
May 2018MaintainsNeutralNeutral

View More Analyst Ratings for OMER
View the Latest Analyst Ratings

Posted-In: Analyst Color News Offerings FDA Analyst Ratings


Related Articles (OMER)

View Comments and Join the Discussion!

Latest Ratings

RMTIInitiates Coverage On10.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Amazon To Launch New Game Console Alongside PlayStation 4, Xbox One

iPhone 5S Will Be Apple's 'Most Successful Launch Ever'